Log in

Vaxart Stock Price, Forecast & Analysis (NASDAQ:VXRT)

$0.31
+0.01 (+3.33 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$0.31
Now: $0.31
$0.33
50-Day Range
$0.27
MA: $0.34
$0.38
52-Week Range
$0.25
Now: $0.31
$5.00
Volume99,200 shs
Average Volume174,660 shs
Market Capitalization$4.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.55
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 million
Book Value$1.20 per share

Profitability

Net Income$-18,000,000.00
Net Margins-222.20%

Miscellaneous

Employees34
Market Cap$4.89 million
Next Earnings Date2/5/2020 (Estimated)
OptionableNot Optionable

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.


Vaxart (NASDAQ:VXRT) Frequently Asked Questions

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

When did Vaxart's stock split? How did Vaxart's stock split work?

Shares of Vaxart reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) posted its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. The biotechnology company earned $0.45 million during the quarter, compared to analysts' expectations of $0.44 million. Vaxart had a negative return on equity of 115.71% and a negative net margin of 222.20%. View Vaxart's Earnings History.

When is Vaxart's next earnings date?

Vaxart is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Vaxart.

What price target have analysts set for VXRT?

2 analysts have issued 1-year price targets for Vaxart's stock. Their forecasts range from $2.00 to $6.00. On average, they expect Vaxart's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,190.3% from the stock's current price. View Analyst Price Targets for Vaxart.

What is the consensus analysts' recommendation for Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

Has Vaxart been receiving favorable news coverage?

Media coverage about VXRT stock has been trending negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vaxart earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Vaxart.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the folowing people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $0.31.

How big of a company is Vaxart?

Vaxart has a market capitalization of $4.89 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

What is Vaxart's official website?

The official website for Vaxart is http://www.vaxart.com/.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]


MarketBeat Community Rating for Vaxart (NASDAQ VXRT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  224 (Thanks for Voting!)
Underperform Votes:  241 (Thanks for Voting!)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel